Rt-PA and stroke: Does IST-3 make it all clear or muddy the waters?

Annals of Emergency Medicine

Volumn 61, Issue 4, 2013, Pages 489-498

  Radecki, Ryan P ^a   Chathampally, Yashwant G ^a   Press, Gregory M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

BLEEDING; BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; EMERGENCY WARD; HUMAN; NOTE; PHYSICIAN; PRIORITY JOURNAL;

EID: 84876570671     PISSN: 01960644     EISSN: 10976760     Source Type: Journal    
DOI: 10.1016/j.annemergmed.2012.12.008     Document Type: Article

References (37)

1. IST-3 Collaborative Group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the Third International Stroke Trial [IST-3]): a randomised controlled trial. Lancet. 2012; 379:2352-2363.
2. Leys D, Cordonnier C. rt-PA for ischaemic stroke: what will the next question be? Lancet. 2012;379:2320-2321.
3. Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet. 2012;379:2364-2372.
4. Djulbegovic B. Articulating and responding to uncertainties in clinical research. J Med Philos. 2012;32:79-98. doi:10.1080/03605310701255719. (Pubitemid 46598161)
5. Sandercock PP, Lindley RR, Wardlaw JJ, et al. Update on the Third International Stroke Trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited. Trials. 2011;12:252-252. doi:10.1186/1745-6215-12-252.
6. Benson H. The nocebo effect: history and physiology. Prev Med. 1997;26(5 pt 1):612-615.
7. Spiegel H. Nocebo: the power of suggestibility. Prev Med. 1997; 26(5 pt 1):616-621.
8. Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev. 2004;(3):CD003974.
9. Wampold BE, Minami T, Tierney SC, et al. The placebo is powerful: estimating placebo effects in medicine and psychotherapy from randomized clinical trials. J Clin Psychol. 2005;61:835-854. (Pubitemid 41153534)
10. Hoffman J, Cooper R. How is more negative evidence being used to support claims of benefit: the curious case of the Third International Stroke Trial (IST-3). Emerg Med Australas. 2012;24: 473-476.
11. Stanley K. Design of randomized controlled trials. Circulation. 2007;115:1164-1169. (Pubitemid 46673177)
12. Smith GD, Ebrahim S. Data dredging, bias, or confounding. BMJ. 2002;325:1437-1438. (Pubitemid 36026785)
13. National Institute of Neurologic Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
14. Spruance SL, Reid JE, Grace M, et al. Hazard ratio in clinical trial. Antimicrob Agents Chemother. 2004;48:2787-2792.
15. National Institute of Neurologic Disorders and Stroke rt-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke. 1997;28:2109-2118.
16. Wardlaw JM, Murray V, Berge E, et al. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2009;(4):CD000213.
17. Saver JL. Optimal end points for acute stroke therapy trials: best ways to measure treatment effects of drugs and devices. Stroke. 2011;42:2356-2362.
18. Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ. 2006;332:1080. (Pubitemid 44365491)
19. Mandava P, Yogesh P, Krumpelman C, et al. A critical review of stroke trial analytical methodology: outcome measures, study design, and correction for imbalances. In: Lapchack PA, Zhang JH, eds. Translational Stroke Research: From Target Selection to Clinical Trials. New York, NY: Springer; 2012:833-862.
20. Quinn TJ, Dawson J, Walters MR, et al. Reliability of the modified Rankin Scale: systematic review. Stroke. 2009;40:3393-3395.
21. Strbian D, Meretoja A, Ahlhelm FJ, et al. Predicting outcome of IV thrombolysis-treated ischemic stroke patients. Neurology. 2012; 78:427-432.
22. Saposnik G, Fang J, Kapral M, et al. The iScore predicts effectiveness of thrombolytic therapy for acute ischemic stroke. Stroke. 2012;43:1315-1322.
23. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008; 359:1317-1329.
24. Saver JL. Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke. 2007;38:3055-3062. (Pubitemid 350035704)
25. Chaudhry S, Schroter S, Smith R, et al. Does declaration of competing interests affect readers' perceptions? a randomized trial. BMJ. 2002;325:1391-1392. (Pubitemid 35477844)
26. Silverman GK, Loewenstein GF, Anderson BL, et al. Failure to discount for conflict of interest when evaluating medical literature: a randomized trial of physicians. J Med Ethics. 2010; 36:265-270.
27. Kesselheim AS, Robertson CT, Myers JA, et al. A randomized study of how physicians interpret research funding disclosures. N Engl J Med. 2012;367:1119-1127.
28. Drazen JM. Believe the data. N Engl J Med. 2012;367:1152-1153.
29. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289:454-469.
30. Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326:1167-1170. (Pubitemid 36649048)
31. Sismondo S. How pharmaceutical industry funding affects trial outcomes: causal structures and responses. Soc Sci Med. 2008; 66:1909-1914. (Pubitemid 351454041)
32. Henry DA, Kerridge IH, Hill SR, et al. Medical specialists and pharmaceutical industry-sponsored research: a survey of the Australian experience. Med J Aust. 2005;182:557-560. (Pubitemid 40823472)
33. Melander H, Ahlqvist-Rastad J, Meijer G, et al. Evidence b(i)ased medicine -selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 2003;326:1171-1173. (Pubitemid 36649049)
34. Handel AE, Patel SV, Pakpoor J, et al. High reprint orders in medical journals and pharmaceutical industry funding: a casecontrol study. BMJ. 2012;344:e4212. doi:10.1136/bmj.e4212.
35. Als-Nielsen B. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA. 2003;290:921-928. (Pubitemid 37430464)
36. Yavchitz A, Boutron I, Bafeta A, et al. Misrepresentation of randomized controlled trials in press releases and news coverage: a cohort study. PLoS Med. 2012;9:e1001308.
37. König R, Ziegler A, BluhmkiE, et al. Predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials. Stroke. 2008;39:1821-1826.